Give patients localized PHN treatment with a favorable safety and tolerability profile

PHN: postherpetic neuralgia.
Not an actual patient.

Light Green Angle Shape

Favorable safety profile1

Adverse Reaction Incidence (%) in Controlled Double-blind Trials in Postherpetic Neuralgia

(Events in >1% of QUTENZA-treated Patients and at Least 1% Greater in the QUTENZA Group than in the Control Group)

Body System
Preferred Term
QUTENZA
60 minutes
(N=622)
%
Control
60 minutes
(N=495)
%
General Disorders and Administration Site Conditions
Application site erythema6354
Application site pain4221
Application site pruritus64
Application site papules63
Application site edema41
Application site swelling21
Application site dryness21
Infections and Infestations
Nasopharyngitis42
Bronchitis21
Sinusitis31
Gastrointestinal Disorders
Nausea52
Vomiting31
Skin and Subcutaneous Tissue Disorder
Pruritus2< 1
Vascular Disorders
Hypertension21

Most common adverse reactions (≥5% and greater than control) are highlighted: application site erythema, application site pain, application site pruritus, and application site papules.

Transient increases in blood pressure (average <10 mm Hg) may occur in patients during and shortly after the QUTENZA treatment. Monitor blood pressure during and following the treatment procedure.

Patients with unstable or poorly controlled hypertension or a recent history of cardiovascular or cerebrovascular events may be at an increased risk of adverse cardiovascular effects. Consider these factors prior to initiating QUTENZA treatment.

The most common adverse reactions were transient and self-limited.1

QUTENZA has a favorable safety profile with no systemic drug-drug interactions

No drug-drug interactions

Treatment flexibility

  • QUTENZA can be used alone or in combination
Low risk for systemic side effects

Low risk for systemic side effects1

  • QUTENZA is non-systemic
  • QUTENZA is non-opioid
  • QUTENZA has no contraindications
Low discontinuation rates

Low discontinuation rates1

  • 1% of QUTENZA patients discontinued in clinical studies due to an adverse event
Patients may experience the following1:
  • Pain at treatment site, which can be treated with a cooling pack or appropriate analgesic medication, if needed
  • Transient increase in blood pressure
  • Sensitivity to heat (eg, during showers, sunlight exposure, vigorous exercise) for a few days